Encouraging industry participation in the EU's Sixth Framework Programme: Issues, barriers and potential solutions
- PDF / 81,765 Bytes
- 6 Pages / 595 x 842 pts (A4) Page_size
- 52 Downloads / 167 Views
Keywords: research, 6FP, EU, industry participation, EU research associations
Encouraging industry participation in the EU’s Sixth Framework Programme: Issues, barriers and potential solutions Wills Hughes-Wilson Date received (in revised form) 16th March, 2004
Abstract There is around A100m annually in the Sixth Framework Programme earmarked exclusively for small and medium-sized enterprises (SMEs) in the life sciences field. That is 15 per cent of the total amount available. But most of it has yet to be allocated. Why are biopharmaceutical SMEs not applying and how can they get access to this money? The Emerging Biopharmaceutical Enterprises (EBE) group teamed up with representatives of the European Commission for the ‘Life Sciences, Genomics and Biotechnology for Health’ Thematic Priority to help companies understand how they can benefit from the Programme and give them an opportunity to add their ideas to it. Attendees came from 60 biopharmaceutical companies, and the programme was structured to allow companies to ask questions, but also put forward ideas to be included in upcoming Calls for the Sixth Framework Programme, as well as suggestions for improving the Seventh Framework Programme to improve industry participation. The event also gave them the chance to ask the Commission representatives specific questions on the administrative aspects of the Programme. The event was organised in conjunction with the Scientific Officers responsible for the different areas in the Programme; and the external experts who advise the Commission on the content of the future calls and the overall strategy for priority areas and activities of research were also invited. This meeting was designed to be as relaxed and open as possible and put the companies directly in contact with the people who implement the Framework Programme. The input from this session based on the feedback of the attendees has been formally forwarded to the Commission and the Thematic Priority Advisory Group. This paper discusses the aims and focus of the Sixth Framework Programme. It provides an overview of the discussion between the EBE and the representatives from the European Commission for the ‘Life Sciences, Genomics and Biotechnology for Health’ Thematic Priority and summarises the key problems and solutions arising therein.
INTRODUCTION
Wills Hughes-Wilson EBE – Emerging Biopharmaceutical Enterprises, Rue du Troˆne 108, B-1050 Brussels, Belgium Tel: + 32 2 626 2561 Fax: + 32 2 626 2566 E-mail: [email protected]
The EU’s Framework Programmes are the main instrument for funding research in Europe. The programmes have been in place since 1984 and each runs for a period of five years. The Sixth Framework Programme became effective in 2002 and will run until 2006. Administered by the Commission’s Directorate-General (DG) for Research,
the Sixth Framework Programme is open to all public and private entities based in the EU and in the accession states, as well as certain other ‘associated’ states. To receive EU financial support, academia, companies and
Data Loading...
